Interleukin-17 prevents oxidative stress from damaging osteoblast formation by inhibiting autophagic degradation of metallothionein-2 by Xueyan Ling, Cuixia Wang, Qin Feng, Tao Zhang

“…Importantly, IL-17A-promoted MT-2 protein levels and -inhibited ROS production were reversed by autophagy activation with rapamycin. Furthermore, IL-17A-inhibited ROS production were blocked by MT-2 silencing. …”
Get full text

Low regulatory T-cells frequency is associated with graft rejection after small bowel transplantation: Clinical and experimental evidence. by Rodrigo Papa-Gobbi, Pablo Stringa, Maria Virginia Gentilini, Ivana Ivanoff, Mariana Machuca, Nidia Monserrat Arreola, Javier Serradilla, Karla Estefanía-Fernández, Paloma Talayero, María Velayos, Elena Sánchez-Zapardiel, Gabriel Gondolesi, Ane Andrés-Moreno, Martin Rumbo, Francisco Hernández-Oliveros

“…In the experimental model, rapamycin-treated animals displayed clinical and histological findings resembling those not receiving immunosuppression treatment. …”
Get full text

Hemodynamic disturbance and mTORC1 activation: Unveiling the biomechanical pathogenesis of thoracic aortic aneurysms in Marfan syndrome by Ming-Yuan Liu, Meili Wang, Junjun Liu, An-Qiang Sun, Chang-Shun He, Xin Cong, Wei Kong, Wei Li

“…Therapeutic administration of rapamycin suppresses mTORC1 activity, leading to the attenuation of aberrant SMC behavior, reduced inflammatory infiltration, and restoration of extracellular matrix integrity—collectively decelerating TAA advancement in our mouse model. …”
Get full text

Alcohol Inhibits Odontogenic Differentiation of Human Dental Pulp Cells by Activating mTOR Signaling by Wei Qin, Qi-Ting Huang, Michael D. Weir, Zhi Song, Ashraf F. Fouad, Zheng-Mei Lin, Liang Zhao, Hockin H. K. Xu

“…Moreover, the pretreatment with rapamycin, a specific mTOR inhibitor, markedly reversed the EtOH-induced odontoblastic differentiation and cell mineralization. …”
Get full text

FOSL2 activates TGF‐β1‐mediated GLUT1/mTOR signaling to promote diabetic kidney disease by Xuelin He, Min Xia, Guanghui Ying, Qien He, Zhaogui Chen, Li Liu, Qiao Zhang, Jianxin Cai

“…Knockdown of FOSL2 inhibited the proliferation and improved ECM deposition of MCs, which were reversed by TGF‐β1. Rapamycin and GLUT1 inhibitor BAY‐876 reversed the promotion effect of FOSL2 on the proliferation of NG‐MCs/HG‐MCs and improved ECM deposition of MCs. …”
Get full text

Staphylococcus aureus induces mitophagy via the HDAC11/IL10 pathway to sustain intracellular survival by Yaji Yang, Haotian Zhou, Feilong Li, Yanhao Zhang, Jianye Yang, Yidong Shen, Ning Hu, Quanming Zou, Leilei Qin, Hao Zeng, Wei Huang

“…The study further explored how the HDAC11/IL10 axis enhances mitophagy to promote intracellular S. aureus survival by using HDAC11 overexpression, siRNA, and rapamycin intervention combined with confocal microscopy and flow cytometry. …”
Get full text

The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma by Jaya Unnithan, Brian I. Rini

“…The most clinically developed targeted therapies in advanced RCC are those that target the vascular endothelial growth factor (VEGF) ligand or receptor (VEGFR) and therapy directed against the mammalian target of rapamycin (mTOR). Sutent and sorafenib are orally available inhibitors of the VEGFR and platelet derived growth factor receptor (PDGFR). …”
Get full text

mTOR Inhibition: From Aging to Autism and Beyond by Matt Kaeberlein

“…The mechanistic target of rapamycin (mTOR) is a highly conserved protein that regulates growth and proliferation in response to environmental and hormonal cues. …”
Get full text

Targeting TCMR-associated cytokine genes for drug screening identifies PPARγ agonists as novel immunomodulatory agents in transplantation by Lu Hu, Lu Hu, Xiaohan Zhang, Xiaohan Zhang, Weiqi Zhang, Weiqi Zhang, Shuai Jin, Shuai Jin, Jie Zhao, Jianming Zheng, Wenli Song, Zhongyang Shen, Zhongyang Shen, Zhongyang Shen

“…The combination of rosiglitazone and rapamycin significantly prolonged graft survival.ConclusionsThis study defined a novel TCMR-associated cytokine gene set that effectively predicts TCMR and identified PPARγ agonists, which prevent TCMR and improve graft survival when combined with rapamycin.…”
Get full text

Metformin in the treatment of colorectal cancer and neuroendocrine tumours by Karolina Daniłowska, Natalia Picheta, Barbara I. Krupska, Anna Rudzińska, Oliwia Burdan, Katarzyna Szklener

“…The biguanide works by inhibiting the mammalian target of rapamycin pathway, activating 5’AMP activated protein kinase, and reducing insulin-like growth factor 1. …”
Get full text

Promising Response with PI3K Inhibitor for a Patient with Heavily Pretreated PIK3CA Mutation Head-and-Neck Cancer by Ming-Jing Lee, Hsiang-Fong Kao

“…Several pathways have been identified in HNSCC, including the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway. The PI3K/AKT/mTOR pathway is frequently dysregulated in various cancers due to activating mutations or amplification of PIK3CA. …”
Get full text

Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas by Laura Eibenschutz, Delia Colombo, Caterina Catricalà

“…Everolimus is an inhibitor of the mammalian target of rapamycin (mTOR) and has been shown to have antineoplastic activity in addition to its use as an immunosuppressive agent for the prevention of organ transplant rejection. …”
Get full text

Immunometabolism of Tregs: mechanisms, adaptability, and therapeutic implications in diseases by Yuming Lu, Yifan Wang, Tiantian Ruan, Yihan Wang, Linling Ju, Mengya Zhou, Luyin Liu, Dengfu Yao, Min Yao

“…The activation, differentiation, and function of Tregs are influenced by various metabolic pathways, such as the Mammalian targets of rapamycin (mTOR) pathway and glycolysis. Correspondingly, activated Tregs can reciprocally impact these metabolic pathways. …”
Get full text

The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas by Elias A. El Habr, Christos Adamopoulos, Georgia Levidou, Aggeliki A. Saetta, Penelope Korkolopoulou, Christina Piperi

“…Aberrant signaling of AKT-mTOR (mammalian target of rapamycin) has been implicated in carcinogenesis. This paper is focused on the impact of deregulated AKT-mTOR signaling components in the clinical outcome and prognosis of human astrocytomas. …”
Get full text

Beneficial Effects of Resveratrol-Mediated Inhibition of the mTOR Pathway in Spinal Cord Injury by Jingying Zhou, Xue Huo, Benson O. A. Botchway, Luyao Xu, Xiaofang Meng, Songou Zhang, Xuehong Liu

“…The mammalian target of rapamycin (mTOR) signaling pathway plays an important role in cell death and inflammation in the acute phase and neuroregeneration in the subacute/chronic phases at different times. …”
Get full text

Cerebral Cavernous Malformation: From Genetics to Pharmacotherapy by Zhuangzhuang Zhang, Jianwen Deng, Weiping Sun, Zhaoxia Wang

“…Medications such as statins, fasudil, rapamycin, and propranolol can alleviate CCM symptoms or hinder its progression by specifically modulating the corresponding targets. …”
Get full text

Protocol for the visualization of pRps6-positive cells in larval zebrafish brains using whole-mount immunofluorescence and light-sheet microscopy by Olga Doszyn, Tomasz Dulski, Justyna Zmorzynska

“…Here, we present a protocol for the visualization of phosphorylated Rps6, a marker of mechanistic target of rapamycin complex 1 (mTORC1) activity, in the zebrafish brains at 5 days post fertilization (dpf), using whole-mount immunofluorescence and light-sheet microscopy. …”
Get full text

Effect of Nitrogen Source and Inorganic Phosphate Concentration on Methanol Utilization and PEX Genes Expression in Pichia pastoris by A. M. Rumjantsev, O. V. Bondareva, M. V. Padkina, E. V. Sambuk

“…Expression of these genes is decreased in media with poor nitrogen sources, such as proline. Addition of rapamycin to the media completely removed repression of AOX1 promoter in media with proline, which allows proposing that Tor-kinase is involved in establishing of nitrogen regulation of this gene. …”
Get full text

Hypoxia-Inducible Factor-1 as a Therapeutic Target in Endometrial Cancer Management by Laura M. S. Seeber, Ronald P. Zweemer, René H. M. Verheijen, Paul J. van Diest

“…In clinical trials for the treatment of advanced and/or recurrent EC are the topoisomerase I inhibitor Topotecan, mTOR-inhibitor Rapamycin, and angiogenesis inhibitor Bevacizumab. …”
Get full text

Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma by J. Martin-Liberal, C. Benson, C. Messiou, C. Fisher, I. Judson

“…The mammalian target of rapamycin (mTOR) pathway has been suggested to play a key role in the mechanisms of hormone resistance. …”
Get full text